When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?
The randomized controlled trial (RCT) is the gold standard for evaluating the causal effects of medications. Limitations of RCTs have led to increasing interest in using real‐world evidence (RWE) to augment RCT evidence and inform decision making on medications. Although RWE can be either randomized...
Uložené v:
| Vydané v: | Clinical pharmacology and therapeutics Ročník 111; číslo 1; s. 108 - 115 |
|---|---|
| Hlavní autori: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.01.2022
|
| Predmet: | |
| ISSN: | 0009-9236, 1532-6535, 1532-6535 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | The randomized controlled trial (RCT) is the gold standard for evaluating the causal effects of medications. Limitations of RCTs have led to increasing interest in using real‐world evidence (RWE) to augment RCT evidence and inform decision making on medications. Although RWE can be either randomized or nonrandomized, nonrandomized RWE can capitalize on the recent proliferation of large healthcare databases and can often answer questions that cannot be answered in randomized studies due to resource constraints. However, the results of nonrandomized studies are much more likely to be impacted by confounding bias, and the existence of unmeasured confounders can never be completely ruled out. Furthermore, nonrandomized studies require more complex design considerations which can sometimes result in design‐related biases. We discuss questions that can help investigators or evidence consumers evaluate the potential impact of confounding or other biases on their findings: Does the design emulate a hypothetical randomized trial design? Is the comparator or control condition appropriate? Does the primary analysis adjust for measured confounders? Do sensitivity analyses quantify the potential impact of residual confounding? Are methods open to inspection and (if possible) replication? Designing a high‐quality nonrandomized study of medications remains challenging and requires broad expertise across a range of disciplines, including relevant clinical areas, epidemiology, and biostatistics. The questions posed in this paper provide a guiding framework for assessing the credibility of nonrandomized RWE and could be applied across many clinical questions. |
|---|---|
| AbstractList | The randomized controlled trial (RCT) is the gold standard for evaluating the causal effects of medications. Limitations of RCTs have led to increasing interest in using real-world evidence (RWE) to augment RCT evidence and inform decision making on medications. Although RWE can be either randomized or nonrandomized, nonrandomized RWE can capitalize on the recent proliferation of large healthcare databases and can often answer questions that cannot be answered in randomized studies due to resource constraints. However, the results of nonrandomized studies are much more likely to be impacted by confounding bias, and the existence of unmeasured confounders can never be completely ruled out. Furthermore, nonrandomized studies require more complex design considerations which can sometimes result in design-related biases. We discuss questions that can help investigators or evidence consumers evaluate the potential impact of confounding or other biases on their findings: Does the design emulate a hypothetical randomized trial design? Is the comparator or control condition appropriate? Does the primary analysis adjust for measured confounders? Do sensitivity analyses quantify the potential impact of residual confounding? Are methods open to inspection and (if possible) replication? Designing a high-quality nonrandomized study of medications remains challenging and requires broad expertise across a range of disciplines, including relevant clinical areas, epidemiology, and biostatistics. The questions posed in this paper provide a guiding framework for assessing the credibility of nonrandomized RWE and could be applied across many clinical questions.The randomized controlled trial (RCT) is the gold standard for evaluating the causal effects of medications. Limitations of RCTs have led to increasing interest in using real-world evidence (RWE) to augment RCT evidence and inform decision making on medications. Although RWE can be either randomized or nonrandomized, nonrandomized RWE can capitalize on the recent proliferation of large healthcare databases and can often answer questions that cannot be answered in randomized studies due to resource constraints. However, the results of nonrandomized studies are much more likely to be impacted by confounding bias, and the existence of unmeasured confounders can never be completely ruled out. Furthermore, nonrandomized studies require more complex design considerations which can sometimes result in design-related biases. We discuss questions that can help investigators or evidence consumers evaluate the potential impact of confounding or other biases on their findings: Does the design emulate a hypothetical randomized trial design? Is the comparator or control condition appropriate? Does the primary analysis adjust for measured confounders? Do sensitivity analyses quantify the potential impact of residual confounding? Are methods open to inspection and (if possible) replication? Designing a high-quality nonrandomized study of medications remains challenging and requires broad expertise across a range of disciplines, including relevant clinical areas, epidemiology, and biostatistics. The questions posed in this paper provide a guiding framework for assessing the credibility of nonrandomized RWE and could be applied across many clinical questions. The randomized controlled trial (RCT) is the gold standard for evaluating the causal effects of medications. Limitations of RCTs have led to increasing interest in using real‐world evidence (RWE) to augment RCT evidence and inform decision making on medications. Although RWE can be either randomized or nonrandomized, nonrandomized RWE can capitalize on the recent proliferation of large healthcare databases and can often answer questions that cannot be answered in randomized studies due to resource constraints. However, the results of nonrandomized studies are much more likely to be impacted by confounding bias, and the existence of unmeasured confounders can never be completely ruled out. Furthermore, nonrandomized studies require more complex design considerations which can sometimes result in design‐related biases. We discuss questions that can help investigators or evidence consumers evaluate the potential impact of confounding or other biases on their findings: Does the design emulate a hypothetical randomized trial design? Is the comparator or control condition appropriate? Does the primary analysis adjust for measured confounders? Do sensitivity analyses quantify the potential impact of residual confounding? Are methods open to inspection and (if possible) replication? Designing a high‐quality nonrandomized study of medications remains challenging and requires broad expertise across a range of disciplines, including relevant clinical areas, epidemiology, and biostatistics. The questions posed in this paper provide a guiding framework for assessing the credibility of nonrandomized RWE and could be applied across many clinical questions. |
| Author | Califf, Robert M. Franklin, Jessica M. Hernandez, Adrian Platt, Richard London, Alex John Watanabe, Jonathan H. Horberg, Michael Dreyer, Nancy A. Simon, Gregory E. |
| Author_xml | – sequence: 1 givenname: Jessica M. surname: Franklin fullname: Franklin, Jessica M. email: Jessica.franklin@optum.com organization: Brigham and Women's Hospital and Harvard Medical School – sequence: 2 givenname: Richard surname: Platt fullname: Platt, Richard organization: Harvard Medical School – sequence: 3 givenname: Nancy A. surname: Dreyer fullname: Dreyer, Nancy A. organization: IQVIA Real World Solutions – sequence: 4 givenname: Alex John surname: London fullname: London, Alex John organization: Carnegie Mellon University – sequence: 5 givenname: Gregory E. surname: Simon fullname: Simon, Gregory E. organization: Kaiser Permanente Washington Health Research Institute – sequence: 6 givenname: Jonathan H. surname: Watanabe fullname: Watanabe, Jonathan H. organization: University of California Irvine – sequence: 7 givenname: Michael surname: Horberg fullname: Horberg, Michael organization: Kaiser Permanente Mid‐Atlantic Permanente Research Institute and Mid‐Atlantic Permanente Medical Group – sequence: 8 givenname: Adrian surname: Hernandez fullname: Hernandez, Adrian organization: Duke Clinical Research Institute – sequence: 9 givenname: Robert M. surname: Califf fullname: Califf, Robert M. organization: Verily Life Sciences and Google Health |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33826756$$D View this record in MEDLINE/PubMed |
| BookMark | eNo9kUtLxDAUhYMoOj7AXyBZuqneJpOkXYkMvsAXzqjLkjS3GmnTmrTK-Ovt4GN1uJyPs7jfNln3rUdC9lM4SgHYcdn1R4wJsUYmqeAskYKLdTIBgDzJGZdbZDvGt_Gc5lm2SbY4z5hUQk5IfH5FT2fa09vWB-1t27gvtHTeD9ZhpPOh69rQ0yddO0uvfIUBfYn0AV90sM6_0LOqwrJ3H-gxRtoGOtcV9kvaVvQWP-kNWlfqmi4C6r5B38eTXbJR6Tri3m_ukMfzs8XsMrm-u7ianV4n5TQFkaDOuLQMlclypTmazCpWKtAKslQZkGBBQyZMlRqwdjqVJWfGWDZ2AoThO-TwZ7cL7fuAsS8aF0usa-2xHWLBRApMylypET34RQfToC264BodlsXfo0Yg-QE-XY3L_z6FYiWgGAUUKwHF7H6xSv4N6j16Bg |
| CitedBy_id | crossref_primary_10_1002_cpt_2465 crossref_primary_10_1016_j_therap_2024_10_062 crossref_primary_10_1016_j_ijrobp_2021_07_1700 crossref_primary_10_1016_j_therap_2024_10_052 crossref_primary_10_1186_s12874_024_02330_2 crossref_primary_10_1016_j_jval_2024_08_002 crossref_primary_10_3390_life13030712 crossref_primary_10_1097_PPO_0000000000000589 crossref_primary_10_1080_15265161_2021_2013977 crossref_primary_10_3389_fphar_2022_966081 crossref_primary_10_1183_23120541_00248_2022 crossref_primary_10_1126_scitranslmed_abn6911 crossref_primary_10_1002_cpt_70027 crossref_primary_10_1002_cpt_2452 crossref_primary_10_1136_bmjopen_2021_058244 crossref_primary_10_1016_j_bja_2023_06_054 crossref_primary_10_3390_ijerph22060894 crossref_primary_10_1016_j_jclinepi_2022_08_015 |
| ContentType | Journal Article |
| Copyright | 2021 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
| Copyright_xml | – notice: 2021 The Authors. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. – notice: 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
| DBID | 24P CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/cpt.2255 |
| DatabaseName | Wiley Online Library Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1532-6535 |
| EndPage | 115 |
| ExternalDocumentID | 33826756 CPT2255 |
| Genre | reviewArticle Journal Article Review |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: R01 HL141505 |
| GroupedDBID | --- --K -Q- .55 .GJ 0R~ 1B1 1CY 1OB 1OC 24P 29B 33P 354 36B 39C 3O- 4.4 52O 53G 5GY 5RE 6J9 70F 8F7 AAESR AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AAQOH AAQQT AAWTL AAYCA AAYOK AAZKR ABCUV ABJNI ABLJU ABQWH ACBNA ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACPOU ACRPL ACXQS ACYXJ ADBBV ADBTR ADKYN ADNMO ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AENEX AEQDE AEUYR AFBPY AFFNX AFFPM AHBTC AI. AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB ASPBG AVWKF AZFZN AZVAB BDRZF BFHJK BMXJE BRXPI C45 CAG COF CS3 DCZOG DPXWK DU5 EBS EE. EJD EMOBN F5P GODZA GWYGA HGLYW IH2 IHE J5H L7B LATKE LEEKS LITHE LOXES LSO LUTES LYRES M41 MEWTI N4W N9A NQ- O9- OPC OVD P2P P2W PALCI RIG RIWAO RJQFR RNTTT ROL RPZ SAMSI SEW SJN SUPJJ TEORI TWZ UHS VH1 WBKPD WH7 WOHZO WXSBR WYJ X7M Y6R YCJ YFH YOC YXB ZGI ZXP ZZTAW AGHNM CGR CUY CVF ECM EIF NPM 7X8 AAMMB AEFGJ AEYWJ AGXDD AGYGG AIDQK AIDYY |
| ID | FETCH-LOGICAL-c4105-ea836d2e7b897a3eb8d72c70a70817b060d0a085bf1b0dd446c32bbd27b0505b3 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 18 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000648483100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0009-9236 1532-6535 |
| IngestDate | Thu Oct 02 05:24:18 EDT 2025 Thu Apr 03 06:58:41 EDT 2025 Wed Jan 22 16:26:41 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Attribution-NonCommercial 2021 The Authors. Clinical Pharmacology & Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4105-ea836d2e7b897a3eb8d72c70a70817b060d0a085bf1b0dd446c32bbd27b0505b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpt.2255 |
| PMID | 33826756 |
| PQID | 2510266977 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | proquest_miscellaneous_2510266977 pubmed_primary_33826756 wiley_primary_10_1002_cpt_2255_CPT2255 |
| PublicationCentury | 2000 |
| PublicationDate | January 2022 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: January 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Clinical pharmacology and therapeutics |
| PublicationTitleAlternate | Clin Pharmacol Ther |
| PublicationYear | 2022 |
| References | 2015; 182 2010; 19 2020; 324 2014; 25 1996; 143 2003; 158 2014; 23 2016; 79 2016; 183 2014; 179 2017; 73 2010; 21 2018; 8 2007; 370 2017; 36 2018; 1 2002; 84 2006; 163 2019; 28 2011; 20 2018; 74 2014; 161 2007; 3 2001; 12 2017; 167 2011; 364 2010; 6 2007; 26 1996; 7 2015; 12 2018; 29 2009; 20 2017; 26 2010 2008; 19 2019; 34 2006; 17 2006; 59 2006; 15 2009 2008 2019; 105 2019; 106 1983; 70 1996; 91 2011; 4 2008; 167 2011; 174 2018; 20 2016; 99 2016; 4 2014; 348 2015; 313 1984; 79 2019 2016; 375 2016 2001; 2 2000; 342 2013 2017; 102 2014; 33 2005; 58 |
| References_xml | – year: 2009 – volume: 79 start-page: 70 year: 2016 end-page: 75 article-title: Specifying a target trial prevents immortal time bias and other self‐inflicted injuries in observational analyses publication-title: J. Clin. Epidemiol. – volume: 4 start-page: 1234 year: 2016 article-title: Comparative effectiveness research using observational data: active comparators to emulate target trials with inactive comparators publication-title: EGEMs – volume: 19 start-page: 766–779 year: 2008 article-title: Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease publication-title: Epidemiology – volume: 163 start-page: 1149 year: 2006 end-page: 1156 article-title: Variable selection for propensity score models publication-title: Am. J. Epidemiol. – volume: 179 start-page: 633 year: 2014 end-page: 640 article-title: The control outcome calibration approach for causal inference with unobserved confounding publication-title: Am. J. Epidemiol. – volume: 8 year: 2018 article-title: EU‐funded initiatives for real world evidence: descriptive analysis of their characteristics and relevance for regulatory decision‐making publication-title: BMJ Open. – volume: 6 year: 2010 article-title: Collaborative double robust targeted maximum likelihood estimation publication-title: Int. J. Biostat. – volume: 370 start-page: 1453 year: 2007 end-page: 1457 article-title: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies publication-title: Lancet – volume: 26 start-page: 20 year: 2007 end-page: 36 article-title: The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials publication-title: Stat. Med. – volume: 58 start-page: 323 year: 2005 end-page: 337 article-title: A review of uses of health care utilization databases for epidemiologic research on therapeutics publication-title: J. Clin. Epidemiol. – volume: 348 start-page: g2866 year: 2014 article-title: Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter‐defibrillators: cohort study of older patients with heart failure publication-title: BMJ – volume: 26 start-page: 734 year: 2007 end-page: 753 article-title: A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study publication-title: Stat. Med. – volume: 34 start-page: 43 year: 2019 end-page: 68 article-title: Automated versus do‐it‐yourself methods for causal inference: lessons learned from a data analysis competition publication-title: Stat. Sci. – volume: 167 start-page: 668–670 year: 2017 article-title: Data sharing and embedded research publication-title: Ann. Intern. Med. – volume: 36 start-page: 1946 year: 2017 end-page: 1963 article-title: Comparing the performance of propensity score methods in healthcare database studies with rare outcomes publication-title: Stat. Med. – volume: 99 start-page: 325 year: 2016 end-page: 332 article-title: Transparency and reproducibility of observational cohort studies using large healthcare databases publication-title: Clin. Pharmacol. Ther. – volume: 167 start-page: 492 year: 2008 end-page: 499 article-title: Immortal time bias in pharmacoepidemiology publication-title: Am. J. Epidemiol. – volume: 29 start-page: 96 year: 2018 end-page: 106 article-title: Using super learner prediction modeling to improve high‐dimensional propensity score estimation publication-title: Epidemiology – volume: 105 start-page: 1513 year: 2019 end-page: 1521 article-title: Evaluation of socioeconomic status indicators for confounding adjustment in observational studies of medication use publication-title: Clin. Pharmacol. Ther. – volume: 3 start-page: 14 year: 2007 article-title: Preference‐based instrumental variable methods for the estimation of treatment effects: assessing validity and interpreting results publication-title: Int. J. Biostat. – volume: 26 start-page: 1018 year: 2017 end-page: 1032 article-title: Reporting to improve reproducibility and facilitate validity assessment for healthcare database studies V1.0 publication-title: Pharmacoepidemiol. Drug Saf. – year: 2008 – volume: 1 year: 2018 article-title: Association of osteoporosis medication use after hip fracture with prevention of subsequent nonvertebral fractures: an instrumental variable analysis publication-title: JAMA Netw. Open – volume: 91 start-page: 444 year: 1996 end-page: 455 article-title: Identification of causal effects using instrumental variables publication-title: J. Am. Stat. Assoc. – volume: 158 start-page: 915 year: 2003 end-page: 920 article-title: Evaluating medication effects outside of clinical trials: new‐user designs publication-title: Am. J. Epidemiol. – volume: 183 start-page: 758 year: 2016 end-page: 764 article-title: Using big data to emulate a target trial when a randomized trial is not available publication-title: Am. J. Epidemiol. – volume: 17 start-page: 360 year: 2006 end-page: 372 article-title: Instruments for causal inference: an epidemiologist’s dream? publication-title: Epidemiology – volume: 161 start-page: 131–138 year: 2014 article-title: Potential bias of instrumental variable analyses for observational comparative effectiveness research publication-title: Ann. Intern. Med. – year: 2019 – volume: 33 start-page: 1685 year: 2014 end-page: 1699 article-title: Metrics for covariate balance in cohort studies of causal effects publication-title: Stat. Med. – volume: 375 start-page: 2293 year: 2016 end-page: 2297 article-title: Real‐world evidence—what is it and what can it tell us publication-title: N. Engl. J. Med. – volume: 174 start-page: 1213 year: 2011 end-page: 1222 article-title: Effects of adjusting for instrumental variables on bias and precision of effect estimates publication-title: Am. J. Epidemiol. – volume: 7 start-page: 335–336 year: 1996 article-title: Confounding by indication publication-title: Epidemiology – volume: 102 start-page: 924 year: 2017 end-page: 933 article-title: When and how can real world data analyses substitute for randomized controlled trials? publication-title: Clin. Pharmacol. Ther. – volume: 15 start-page: 291 year: 2006 end-page: 303 article-title: Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics publication-title: Pharmacoepidemiol. Drug Saf. – volume: 19 start-page: 537 year: 2010 end-page: 554 article-title: Instrumental variable methods in comparative safety and effectiveness research publication-title: Pharmacoepidemiol. Drug Saf. – volume: 20 start-page: 974 year: 2018 end-page: 984 article-title: Claims‐based studies of oral glucose‐lowering medications can achieve balance in critical clinical variables only observed in electronic health records publication-title: Diabetes Obes. Metab. – volume: 12 year: 2015 article-title: The REporting of studies Conducted using Observational Routinely‐collected health Data (RECORD) statement publication-title: PLoS Med. – volume: 20 start-page: 512 year: 2009 end-page: 522 article-title: High‐dimensional propensity score adjustment in studies of treatment effects using health care claims data publication-title: Epidemiology – volume: 313 start-page: 793 year: 2015 end-page: 794 article-title: Sharing clinical trial data: maximizing benefits, minimizing risk publication-title: JAMA – volume: 4 start-page: 8–11 year: 2011 article-title: An overview of randomization techniques: an unbiased assessment of outcome in clinical research publication-title: J. Hum. Reprod. Sci. – volume: 70 start-page: 41 year: 1983 end-page: 55 article-title: The central role of the propensity score in observational studies for causal effects publication-title: Biometrika – volume: 26 start-page: 1033 year: 2017 end-page: 1039 article-title: Good practices for real‐world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making publication-title: Pharmacoepidemiol. Drug Saf. – volume: 17 start-page: 268 year: 2006 end-page: 275 article-title: Evaluating short‐term drug effects using a physician‐specific prescribing preference as an instrumental variable publication-title: Epidemiology – year: 2016 – volume: 12 start-page: 682 year: 2001 end-page: 689 article-title: Paradoxical relations of drug treatment with mortality in older persons publication-title: Epidemiology – year: 2010 – volume: 106 start-page: 103 year: 2019 end-page: 115 article-title: A structured preapproval and postapproval comparative study design framework to generate valid and transparent real‐world evidence for regulatory decisions publication-title: Clin. Pharmacol. Ther – volume: 73 start-page: 1111 year: 2017 end-page: 1122 article-title: Outcome‐adaptive lasso: variable selection for causal inference publication-title: Biometrics – volume: 364 start-page: 498 year: 2011 end-page: 499 article-title: Developing the Sentinel System—a national resource for evidence development publication-title: N. Engl. J. Med. – volume: 25 start-page: 126 year: 2014 end-page: 133 article-title: Prospective cohort studies of newly marketed medications: using covariate data to inform the design of large‐scale studies publication-title: Epidemiology – volume: 59 start-page: 819 year: 2006 end-page: 828 article-title: Selective prescribing led to overestimation of the benefits of lipid‐lowering drugs publication-title: J. Clin. Epidemiol. – volume: 21 start-page: 383–388 year: 2010 article-title: Negative controls: a tool for detecting confounding and bias in observational studies publication-title: Epidemiology – volume: 26 start-page: 459 year: 2017 end-page: 468 article-title: Prevalent new‐user cohort designs for comparative drug effect studies by time‐conditional propensity scores: Prevalent New‐user Designs publication-title: Pharmacoepidemiol. Drug Saf. – volume: 74 start-page: 8 year: 2018 end-page: 17 article-title: Covariate selection with group lasso and doubly robust estimation of causal effects publication-title: Biometrics – volume: 182 start-page: 840 year: 2015 end-page: 845 article-title: Counterpoint: the treatment decision design publication-title: Am. J. Epidemiol. – volume: 79 start-page: 516 year: 1984 end-page: 524 article-title: Reducing bias in observational studies using subclassification on the propensity score publication-title: J. Am. Stat. Assoc. – volume: 20 start-page: 849 year: 2011 end-page: 857 article-title: Confounding adjustment via a semi‐automated high‐dimensional propensity score algorithm: an application to electronic medical records publication-title: Pharmacoepidemiol. Drug Saf. – volume: 105 start-page: 867 year: 2019 end-page: 877 article-title: Evaluating the use of nonrandomized real‐world data analyses for regulatory decision making publication-title: Clin. Pharmacol. Therap. – volume: 23 start-page: 830 year: 2014 end-page: 838 article-title: Instrumental variable applications using nursing home prescribing preferences in comparative effectiveness research publication-title: Pharmacoepidemiol. Drug Saf. – volume: 2 start-page: 259 year: 2001 end-page: 278 article-title: Estimation of causal effects using propensity score weighting: an application to data on right heart catheterization publication-title: Health Serv. Outcomes Res. Methodol. – volume: 324 start-page: 625–626 year: 2020 article-title: Weighing the benefits and risks of proliferating observational treatment assessments: observational cacophony, randomized harmony publication-title: JAMA – volume: 28 start-page: 532 year: 2019 end-page: 554 article-title: Scalable collaborative targeted learning for high‐dimensional data publication-title: Stat. Methods Med. Res. – volume: 143 start-page: 971 year: 1996 end-page: 978 article-title: Prior to use of estrogen replacement therapy, are users healthier than nonusers? publication-title: Am. J. Epidemiol. – volume: 28 start-page: 1044 year: 2019 end-page: 1063 article-title: Collaborative‐controlled LASSO for constructing propensity score‐based estimators in high‐dimensional data publication-title: Stat. Methods Med. Res. – volume: 84 start-page: 151 year: 2002 end-page: 161 article-title: Propensity score‐matching methods for nonexperimental causal studies publication-title: Rev. Econ. Stat. – volume: 342 start-page: 1887 year: 2000 end-page: 1892 article-title: Randomized, controlled trials, observational studies, and the hierarchy of research designs publication-title: N. Engl. J. Med. – year: 2013 |
| SSID | ssj0004988 |
| Score | 2.4824662 |
| SecondaryResourceType | review_article |
| Snippet | The randomized controlled trial (RCT) is the gold standard for evaluating the causal effects of medications. Limitations of RCTs have led to increasing... |
| SourceID | proquest pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 108 |
| SubjectTerms | Bias Confounding Factors, Epidemiologic Data Analysis Evidence-Based Medicine Humans Non-Randomized Controlled Trials as Topic - methods Therapeutics - adverse effects |
| Title | When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments? |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcpt.2255 https://www.ncbi.nlm.nih.gov/pubmed/33826756 https://www.proquest.com/docview/2510266977 |
| Volume | 111 |
| WOSCitedRecordID | wos000648483100001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF60evDi-1FfjCA9NbrZpNn0JFIsClqC1tJbyD5SejApTSvUX-9sHi2CB8HL5rBZCMzs5Jvd-b4h5FrINpdoWyu2PW1hwIstwaQwTQSolFS5Or9oHzzzXs8fDttBWVVpuDCFPsTywM3sjDxemw0eiex2JRoqJ7MbdMbWOtmwbcc3bRuYG6w4kW3fr7qoIYjxKuFZym6rlb-Byp8YNf_JdHf-83m7ZLuElnBf-MIeWdPJPmkEhTb1ogn9FdUqa0IDgpVq9eKAZBiWE-hECfRMx4FEpR_jL62gLDQE0_4ToToMELgreKp4gvCqR8bJkhEUQshl9IR0Cm9RrGcLSGPAUArllRD0q9L27O6QvHcf-p1Hq-zIYElTDmrpyHc8xTQXfptHjha-4kxyGnFEFlxQjyoaIYgTsS2oUphqSocJoRjOIdQSzhGpJWmiTwjErlRceYYHq11u-LLUVS3JheLUQ8xaJ1eVcUL0eHONESU6nWchIjJMHD0ErnVyXFgtnBTSHCEm3AxTIFzdyI2znCjUmVmIZgmNWcJO0DfP07--eEa2mGE-5Kcv56Q2m871BdmUn7NxNr3MfQ9HPvRx7AUv3z413zM |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEB50FfTi-_0aQfZkNWZr08WDyKIorkvRKt5K86h4sF22q7D-eid9uAgeBE89pIHATCbfTPJ9A3AgVVsosq2TnHjGoYCXOJIraZsIMKWYdk1x0f7UFb2e__zcDibgrObClPoQ3wU3uzOKeG03uC1IH49VQ1V_eETeeDoJUy4dMtbJuRuMSZFt36_bqBGK8WrlWcaP65m_ocqfILU4Za7m_7W-BZirwCVelN6wCBMmXYJmUKpTjw4xHJOt8kNsYjDWrR4tQ06BOcVOnGLP9hxIdfb2-mk0Vk8N0TYAJbCOTwTdNd7UTEG8Ny_WzdIXLKWQq_iJ2QAf4sQMR5glSMEUq0shDOvH7fn5CjxeXYada6fqyeAo-yDUMbHf8jQ3QvptEbeM9LXgSrBYELYQknlMs5hgnExOJNOakk3V4lJqTmMEtmRrFRpplpp1wMRVWmjPMmGNKyxjlrn6VAmpBfMItW7Afm2diHzeXmTEqcne84gwGaWOHkHXDVgrzRb1S3GOiFJuTkkQzW4W1vkeKPWZeURmiaxZok4Q2u_mX3_cg5nr8K4bdW96t1swyy0PoqjFbENjOHg3OzCtPoav-WC3cMQvDY7hKg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB58IV58v18jSE_GbrdpNsWDSLUoSglaxVvIPiIeTEpThfrrnc3DIngQPOWwWQjM7OSbnfm-ATiWqi0U2daJG55xKODFjuRK2iECTCmmXZMX2p_uRK_nPz-3gyk4q7gwhT7E94WbPRl5vLYH3Ax0XJ-ohqrB6JS8sTUNs25LNKxLczeYkCLbvl-NUSMU41XKs4zXq52_ocqfIDX_y3SX_vV9y7BYgku8KLxhBaZMsgq1oFCnHp9gf0K2yk6whsFEt3q8BhkF5gQ7UYI9O3Mg0enb66fRWLYaoh0ASmAdnwi6a7ypmIJ4b16smyUvWEghl_ET0yE-RLEZjTGNkYIplkUh7FfN7dn5Ojx2r_qda6ecyeAo2xDqmMhvepobIf22iJpG-lpwJVgkCFsIyTymWUQwTsYNybSmZFM1uZSa0xqBLdncgJkkTcwWYOwqLbRnmbDGFZYxy1zdUkJqwTxCrdtwVFknJJ-3hYwoMel7FhImo9TRI-i6DZuF2cJBIc4RUsrNKQmi3bXcOt8LhT4zD8ksoTVL2An69rnz1xcPYT647IZ3N73bXVjglgaRX8Xswcxo-G72YU59jF6z4UHuh1_dIOCu |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=When+Can+Nonrandomized+Studies+Support+Valid+Inference+Regarding+Effectiveness+or+Safety+of+New+Medical+Treatments%3F&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Franklin%2C+Jessica+M.&rft.au=Platt%2C+Richard&rft.au=Dreyer%2C+Nancy+A.&rft.au=London%2C+Alex+John&rft.date=2022-01-01&rft.issn=0009-9236&rft.eissn=1532-6535&rft.volume=111&rft.issue=1&rft.spage=108&rft.epage=115&rft_id=info:doi/10.1002%2Fcpt.2255&rft.externalDBID=10.1002%252Fcpt.2255&rft.externalDocID=CPT2255 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-9236&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-9236&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-9236&client=summon |